$RGEN
REPLIGEN CORP Stock $rgen

$rgen Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-K Financial Statement

#000119312517054220 Filed on February 23, 2017

Income Statement

Concept	2015 Q4	2015 Q3	2015 Q2
Revenue	$21.45M	$19.81M	$21.46M
YoY Change	30.84%	29.69%	37.98%
Cost Of Revenue	$10.15M	$8.444M	$8.586M
YoY Change	25.53%	21.83%	28.71%
Gross Profit	$11.30M	$11.37M	$12.87M
YoY Change	36.01%	36.22%	44.94%
Gross Profit Margin	52.69%	57.38%	59.99%
Selling, General & Admin	$6.473M	$5.959M	$6.242M
YoY Change	30.11%	33.28%	44.29%
% of Gross Profit	57.28%	52.41%	48.5%
Research & Development	$1.431M	$1.490M	$1.252M
YoY Change	7.76%	-9.7%	-12.45%
% of Gross Profit	12.66%	13.1%	9.73%
Depreciation & Amortization	$1.140M	$1.150M	$1.150M
YoY Change	7.55%	4.55%	18.56%
% of Gross Profit	10.09%	10.11%	8.93%
Operating Expenses	$7.904M	$7.449M	$7.494M
YoY Change	25.4%	21.7%	30.19%
Operating Profit	$1.428M	$3.688M	$4.609M
YoY Change	2240.98%	66.43%	48.39%
Interest Expense	$8.000K	$8.000K	$8.000K
YoY Change	-33.33%	-27.27%	-38.46%
% of Operating Profit	0.56%	0.22%	0.17%
Other Income/Expense, Net	-$270.0K	-$38.00K	-$269.0K
YoY Change	-301.49%	171.43%	-513.85%
Pretax Income	$1.194M	$3.679M	$4.351M
YoY Change	393.39%	63.15%	34.17%
Income Tax	$929.0K	$1.141M	$738.0K
% Of Pretax Income	77.81%	31.01%	16.96%
Net Earnings	$265.0K	$2.538M	$3.613M
YoY Change	-166.58%	73.12%	27.89%
Net Earnings / Revenue	1.24%	12.81%	16.84%
Basic Earnings Per Share	$0.01	$0.08	$0.11
Diluted Earnings Per Share	$0.01	$0.08	$0.11
COMMON SHARES
Basic Shares Outstanding	32.95M shares	32.93M shares	32.87M shares
Diluted Shares Outstanding	33.58M shares	33.69M shares	33.67M shares

Balance Sheet

Concept	2015 Q4	2015 Q3	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$71.80M	$68.90M	$63.20M
YoY Change	22.74%	27.36%	26.4%
Cash & Equivalents	$54.09M	$48.08M	$40.01M
Short-Term Investments	$17.70M	$20.80M	$23.20M
Other Short-Term Assets	$22.00K	$1.100M	$800.0K
YoY Change	-4.35%	-8.33%	-50.0%
Inventory	$18.00M	$15.90M	$14.31M
Prepaid Expenses
Receivables	$11.30M	$10.32M	$14.42M
Other Receivables	$100.0K	$100.0K	$500.0K
Total Short-Term Assets	$103.3M	$96.28M	$93.27M
YoY Change	27.56%	27.2%	26.28%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.80M	$13.97M	$14.46M
YoY Change	-4.99%	5.93%	15.25%
Goodwill	$14.35M	$14.35M	$14.35M
YoY Change	1.14%	1.43%	7.45%
Intangibles	$12.76M	$13.15M	$13.59M
YoY Change	-12.85%	-14.3%	-15.67%
Long-Term Investments	$1.600M	$1.700M	$1.200M
YoY Change	-55.56%	-83.0%	-89.92%
Other Assets	$500.0K	$500.0K	$500.0K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$42.99M	$43.57M	$44.08M
YoY Change	-9.21%	-18.0%	-20.14%
TOTAL ASSETS
Total Short-Term Assets	$103.3M	$96.28M	$93.27M
Total Long-Term Assets	$42.99M	$43.57M	$44.08M
Total Assets	$146.2M	$139.9M	$137.3M
YoY Change	13.99%	8.55%	6.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.724M	$2.951M	$4.303M
YoY Change	74.06%	6.81%	10.46%
Accrued Expenses	$12.06M	$12.76M	$11.52M
YoY Change	76.81%	65.51%	134.21%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$18.78M	$15.71M	$15.83M
YoY Change	75.82%	50.03%	79.52%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$4.708M	$2.693M	$3.296M
YoY Change	-19.92%	-26.97%	-29.3%
Total Long-Term Liabilities	$4.708M	$2.693M	$3.296M
YoY Change	-19.92%	-26.97%	-29.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.78M	$15.71M	$15.83M
Total Long-Term Liabilities	$4.708M	$2.693M	$3.296M
Total Liabilities	$23.49M	$18.40M	$19.12M
YoY Change	41.83%	29.97%	41.87%
SHAREHOLDERS EQUITY
Retained Earnings	-$71.54M	-$71.81M	-$74.35M
YoY Change	-11.55%	-10.79%	-9.29%
Common Stock	$202.9M	$202.0M	$200.8M
YoY Change	2.25%	61663.56%	61373.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$122.7M	$121.5M	$118.2M
YoY Change
Total Liabilities & Shareholders Equity	$146.2M	$139.9M	$137.3M
YoY Change	13.99%	8.55%	6.43%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2015 Q2
OPERATING ACTIVITIES
Net Income	$265.0K	$2.538M	$3.613M
YoY Change	-166.58%	73.12%	27.89%
Depreciation, Depletion And Amortization	$1.140M	$1.150M	$1.150M
YoY Change	7.55%	4.55%	18.56%
Cash From Operating Activities	$3.350M	$6.590M	$7.410M
YoY Change	91.43%	4.11%	219.4%
INVESTING ACTIVITIES
Capital Expenditures	-$570.0K	-$320.0K	-$470.0K
YoY Change	-78.41%	-81.61%	-24.19%
Acquisitions
YoY Change
Other Investing Activities	$3.250M	$1.930M	$690.0K
YoY Change	128.87%	9550.0%	-104.01%
Cash From Investing Activities	$2.670M	$1.620M	$220.0K
YoY Change	-318.85%	-194.19%	-101.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-60.00K	240.0K	290.0K
YoY Change	-107.5%	-152.17%	-65.48%
NET CHANGE
Cash From Operating Activities	3.350M	6.590M	7.410M
Cash From Investing Activities	2.670M	1.620M	220.0K
Cash From Financing Activities	-60.00K	240.0K	290.0K
Net Change In Cash	5.960M	8.450M	7.920M
YoY Change	348.12%	103.61%	-154.06%
FREE CASH FLOW
Cash From Operating Activities	$3.350M	$6.590M	$7.410M
Capital Expenditures	-$570.0K	-$320.0K	-$470.0K
Free Cash Flow	$3.920M	$6.910M	$7.880M
YoY Change	-10.71%	-14.37%	168.03%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1407000
CY2017Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	33845474	shares
CY2016Q2	dei	Entity Public Float EntityPublicFloat	915057854
CY2011Q3	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	200000
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	84124000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39830000
CY2014Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	1956000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	111732000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35363000
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32949353	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32949353	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1054584	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.28
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-71542000
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4708000
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	146237000
CY2015Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	343000
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4680000
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	258000
CY2015Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	501000
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8566000
CY2015Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	1899000
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6724000
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	122748000
CY2015Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	451000
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	329000
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	202527000
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16496000
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	269000
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1289000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4885000
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	31000
CY2015Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	166000
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2204000
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18781000
CY2015Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	6788000
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18514000
CY2015Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	501000
CY2015Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	4480000
CY2015Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12057000
CY2015Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	18000
CY2015Q4	us-gaap	Assets Current AssetsCurrent	103252000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Contingencies DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies	2126000
CY2015Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1586000
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	22000
CY2015Q4	us-gaap	Prepaid Insurance PrepaidInsurance	455000
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13801000
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	450000
CY2015Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	558000
CY2015Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	17682000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54092000
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12389000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1820000
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	12755000
CY2015Q4	us-gaap	Inventory Net InventoryNet	17998000
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11300000
CY2015Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	42985000
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	19326000
CY2015Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	425000
CY2015Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	206000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1079000
CY2015Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	2808000
CY2015Q4	us-gaap	Interest Receivable InterestReceivable	63000
CY2015Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	13758000
CY2015Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	82000
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	30297000
CY2015Q4	us-gaap	Assets Assets	146237000
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	19315000
CY2015Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	1633000
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	18564000
CY2015Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	50000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	4355000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	1150000
CY2015Q4	us-gaap	Goodwill Goodwill	14346000
CY2015Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	17640000
CY2015Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	10671000
CY2015Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5741000
CY2015Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	13306000
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2098000
CY2015Q4	us-gaap	Prepaid Taxes PrepaidTaxes	105000
CY2015Q4	rgen	Prepaid Services And Professional Fees PrepaidServicesAndProfessionalFees	689000
CY2016Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	15	Investment
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	16.82
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33844074	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1821576	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	837660	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33844074	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	427310	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	11.11
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	882748	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.88
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Share Price SharePrice	30.82
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-59861000
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3802000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2584000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	14304000
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	288913000
CY2016Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	435000
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5586000
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	408000
CY2016Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	13394000
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-13749000
CY2016Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	1792000
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5061000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	168764000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	2485000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	2523000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	2485000
CY2016Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2103000
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	338000
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	242036000
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	19332000
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	411000
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1407000
CY2016Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	43679000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	2491000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6695000
CY2016Q4	us-gaap	Contractual Obligation ContractualObligation	10008000
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	23000
CY2016Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1692000
CY2016Q4	us-gaap	Other Liabilities Fair Value Disclosure OtherLiabilitiesFairValueDisclosure	0
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1798000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	1736000
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21075000
CY2016Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	6119000
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	9979000
CY2016Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	7346000
CY2016Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	95272000
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	6119000
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16014000
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	7000
CY2016Q4	us-gaap	Assets Current AssetsCurrent	184153000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Contingencies DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies	3333000
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2789000
CY2016Q4	us-gaap	Other Assets Current OtherAssetsCurrent	42000
CY2016Q4	us-gaap	Prepaid Insurance PrepaidInsurance	356000
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14956000
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	450000
CY2016Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	8617000
CY2016Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	553000
CY2016Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	19547000
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	9758000
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	122233000
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12284000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2036000
CY2016Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	9555000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2845000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2624000
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	29806000
CY2016Q4	us-gaap	Inventory Net InventoryNet	24696000
CY2016Q4	us-gaap	Other Assets Fair Value Disclosure OtherAssetsFairValueDisclosure	0
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	12140000
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15194000
CY2016Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	104760000
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	19552000
CY2016Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	1264000
CY2016Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	5000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1722000
CY2016Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	3218000
CY2016Q4	us-gaap	Interest Receivable InterestReceivable	29000
CY2016Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	15214000
CY2016Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	839000
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	34288000
CY2016Q4	us-gaap	Assets Assets	288913000
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	19547000
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	19552000
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	19547000
CY2016Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	21270000
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	11291000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	6950000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	1895000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	2022000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2311000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2657000
CY2016Q4	us-gaap	Goodwill Goodwill	59548000
CY2016Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	36501000
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	14954000
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	6953000
CY2016Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	14592000
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1644000
CY2016Q4	us-gaap	Prepaid Taxes PrepaidTaxes	73000
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	12733000
CY2016Q4	rgen	Deferred Tax Liabilities Conversion Option On Convertible Notes DeferredTaxLiabilitiesConversionOptionOnConvertibleNotes	6048000
CY2016Q4	rgen	Impact Of Credit Risk On Fair Value Of Derivatives ImpactOfCreditRiskOnFairValueOfDerivatives	0
CY2016Q4	rgen	Prepaid Services And Professional Fees PrepaidServicesAndProfessionalFees	586000
CY2016Q4	rgen	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Equity Instruments Other Than Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsNonvestedNumberOfShares	719579	shares
CY2007Q2	rgen	Common Stock Purchase Warrants Exercise Price Per Share CommonStockPurchaseWarrantsExercisePricePerShare	0.01
CY2007Q2	rgen	Warrant Term WarrantTerm	P7Y
CY2007Q2	rgen	Stock Issued During Period Shares Common Stock Warrants StockIssuedDuringPeriodSharesCommonStockWarrants	150000	shares
CY2014Q1	rgen	Lease Commencement Date LeaseCommencementDate	2014-08-01
CY2014Q1	rgen	Lease Agreement Term LeaseAgreementTerm	P8Y1M
CY2011Q3	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-05-31
CY2011Q3	rgen	Lease Agreement Area LeaseAgreementArea	55694	sqft
CY2011Q3	rgen	Lease Agreement Term LeaseAgreementTerm	P11Y
CY2001	rgen	Lease Agreement Area LeaseAgreementArea	25000	sqft
CY2001	rgen	Lease Agreement Term LeaseAgreementTerm	P10Y
CY2007	rgen	Lease Agreement Area LeaseAgreementArea	2500	sqft
CY2007	rgen	Lease Agreement Term LeaseAgreementTerm	P5Y
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	307475	shares
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.25
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.065	pure
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	18401000
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y6M
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.5171	pure
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33263667	shares
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32497657	shares
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.011	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5100	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0188	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.45
CY2014	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	766010	shares
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.25
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.132	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0211	pure
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.267	pure
CY2014	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	727000
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	751000
CY2014	us-gaap	Revenues Revenues	63548000
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5602000
CY2014	us-gaap	Investment Income Net InvestmentIncomeNet	309000
CY2014	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1681000
CY2014	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	60431000
CY2014	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	27508000
CY2014	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	21236000
CY2014	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-28000
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	10691000
CY2014	us-gaap	Net Income Loss NetIncomeLoss	8170000
CY2014	us-gaap	Increase In Restricted Cash IncreaseInRestrictedCash	250000
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	860000
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1597000
CY2014	us-gaap	Gain Loss On Investments GainLossOnInvestments	0
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	399000
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1766000
CY2014	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	4000000
CY2014	us-gaap	Royalty Revenue RoyaltyRevenue	3117000
CY2014	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-7743000
CY2014	us-gaap	Income Taxes Paid IncomeTaxesPaid	2547000
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	188000
CY2014	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-6557000
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	820000
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	12290000
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1152000
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	11138000
CY2014	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-35000
CY2014	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2072000
CY2014	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	295000
CY2014	us-gaap	Depreciation Depreciation	2594000
CY2014	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-4756000
CY2014	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	214000
CY2014	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	2821000
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2968000
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2288000
CY2014	us-gaap	Interest Expense InterestExpense	50000
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-19792000
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	1766000
CY2014	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2480000
CY2014	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4020000
CY2014	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	3787000
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17154000
CY2014	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-67000
CY2014	us-gaap	Costs And Expenses CostsAndExpenses	52857000
CY2014	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2489000
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1680000
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2735000
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5609000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	9656000
CY2014	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1425000
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4467000
CY2014	us-gaap	Cost Of Goods Sold CostOfGoodsSold	28022000
CY2014	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	0
CY2014	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2014	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-1471000
CY2014	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-25000
CY2014	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	122000
CY2014	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	727000
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1680000
CY2014	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	34804000
CY2014	rgen	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.015	pure
CY2014	rgen	Provision For Deferred Income Tax Expense Benefit ProvisionForDeferredIncomeTaxExpenseBenefit	488000
CY2014	rgen	Increase Decrease In Noncurrent Liabilities IncreaseDecreaseInNoncurrentLiabilities	-1036000
CY2014	rgen	Income Tax Reconciliation Permanent Differences IncomeTaxReconciliationPermanentDifferences	-172000
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	196209	shares
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.28
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.091	pure
CY2015	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P10Y
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	15053000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.5189	pure
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33577091	shares
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32881940	shares
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.042	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5009	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0167	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	16.05
CY2015	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	695151	shares
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.28
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.142	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.027	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.009	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0203	pure
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.304	pure
CY2015	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1216000
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1536000
CY2015	us-gaap	Revenues Revenues	83537000
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2628000
CY2015	us-gaap	Investment Income Net InvestmentIncomeNet	136000
CY2015	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	115000
CY2015	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	866000
CY2015	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	83537000
CY2015	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	20168000
CY2015	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	99000
CY2015	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	22000
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	13764000
CY2015	us-gaap	Net Income Loss NetIncomeLoss	9345000
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6149000
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3729000
CY2015	us-gaap	Gain Loss On Investments GainLossOnInvestments	0
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	6552000
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3598000
CY2015	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2815000
CY2015	us-gaap	Income Taxes Paid IncomeTaxesPaid	4948000
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-445000
CY2015	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2793000
CY2015	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-158000
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	277000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	15913000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-2490000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	13423000
CY2015	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-1000
CY2015	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	4083000
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-118000
CY2015	us-gaap	Depreciation Depreciation	2996000
CY2015	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-1882000
CY2015	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	295000
CY2015	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	3507000
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4078000
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3024000
CY2015	us-gaap	Interest Expense InterestExpense	32000
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	4791000
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	3598000
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3745000
CY2015	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4594000
CY2015	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	4564000
CY2015	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	24699000
CY2015	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	276000
CY2015	us-gaap	Costs And Expenses CostsAndExpenses	69773000
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1592000
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	767000
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2619000
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5740000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3638000
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1600000
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	18729000
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	35251000
CY2015	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	0
CY2015	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2015	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-1910000
CY2015	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-358000
CY2015	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	563000
CY2015	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1216000
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	866000
CY2015	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	27587000
CY2015	rgen	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.009	pure
CY2015	rgen	Provision For Deferred Income Tax Expense Benefit ProvisionForDeferredIncomeTaxExpenseBenefit	333000
CY2015	rgen	Increase Decrease In Noncurrent Liabilities IncreaseDecreaseInNoncurrentLiabilities	2115000
CY2015	rgen	Income Tax Reconciliation Permanent Differences IncomeTaxReconciliationPermanentDifferences	118000
CY2008	rgen	Lease Agreement Area LeaseAgreementArea	7350	sqft
CY2008	rgen	Lease Agreement Term LeaseAgreementTerm	P2Y
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	381686	shares
CY2016	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2016	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016	dei	Document Type DocumentType	10-K
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.34
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.169	pure
CY2016	dei	Entity Central Index Key EntityCentralIndexKey	0000730272
CY2016	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2016	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P13Y
CY2016	us-gaap	Nature Of Operations NatureOfOperations	<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left"><b>1.</b></td> <td valign="top" align="left"><b>Organization and Nature of Business</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Repligen Corporation (NASDAQ:RGEN) is a bioprocessing company focused on the development, manufacture and commercialization of highly innovative products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products (Protein A affinity ligands, cell culture growth factors), chromatography products (OPUS pre-packed columns, chromatography resins, ELISA kits), and filtration products (XCell ATF Systems, Sius TFF cassettes). The Company’s bioprocessing products are sold to major life sciences companies, biopharmaceutical development companies and contract manufacturing organizations worldwide. The Protein A ligands and growth factor products that the Company manufactures are components of chromatography resins and cell culture media, respectively</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The Company is the leading manufacturer of Protein A ligands, a critical component of Protein A resins that are the industry standard for downstream separation and purification of monoclonal antibody-based therapeutics. The Company’s growth factors are used in upstream processes to accelerate cell growth and productivity in a bioreactor. The Company’s innovative line of OPUS chromatography columns, used in downstream processes for bench-scale through clinical-scale purification needs, are delivered pre-packed with its customers’ choice of resin and volume. The Company’s XCell ATF Systems, available in stainless steel and single-use configurations, continuously eliminate waste from a bioreactor, to accelerate and increase productivity in upstream processes. Single-use Sius TFF cassettes and hardware are used for biologic drug concentration in downstream processes. Repligen’s corporate headquarters are in Waltham, Massachusetts (USA) and its manufacturing facilities are located in Waltham, Massachusetts; Shrewsbury, Massachusetts; Lund, Sweden; and Weingarten, Germany.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> The Company is subject to a number of risks typically associated with companies in the biotechnology industry. These risks principally include the Company’s dependence on key customers, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with the FDA and other governmental regulations and approval requirements, as well as the ability to grow the Company’s business and obtain adequate funding to finance this growth.</p> </div>
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	7521000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.5101	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	88592	shares
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7.72
CY2016	dei	Trading Symbol TradingSymbol	RGEN
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34098898	shares
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33572883	shares
CY2016	dei	Amendment Flag AmendmentFlag	false
CY2016	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Concentrations of Credit Risk and Significant Customers</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Financial instruments that subject the Company to significant concentrations of credit risk primarily consist of cash and cash equivalents, marketable securities and accounts receivable. Per the Company’s investment policy, cash equivalents and marketable securities are invested in financial instruments with high credit ratings and credit exposure to any one issue, issuer (with the exception of U.S. treasury obligations) and type of instrument is limited. At December 31, 2016 and 2015, the Company had no investments associated with foreign exchange contracts, options contracts or other foreign hedging arrangements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Concentration of credit risk with respect to accounts receivable is limited to customers to whom the Company makes significant sales. While a reserve for the potential write-off of accounts receivable is maintained, the Company has not written off any significant accounts to date. To control credit risk, the Company performs regular credit evaluations of its customers’ financial condition.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Revenue from significant customers as a percentage of the Company’s total revenue is as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">  </p> <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"> <b>Years ended December 31,</b></td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> GE Healthcare</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">29</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> MilliporeSigma</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">28</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">29</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Significant accounts receivable balances as a percentage of the Company’s total trade accounts receivable and royalties and other receivable balances are as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="55%"></td> <td valign="bottom" width="22%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="21%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December 31, 2016</b></td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December 31, 2015</b></td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> GE Healthcare</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">26</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> MilliporeSigma</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">32</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"> Bioprocessing Customer C</p> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1</td> <td valign="bottom" nowrap="nowrap">% </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21</td> <td valign="bottom" nowrap="nowrap">% </td> </tr> </table> </div>
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.028	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5085	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0151	pure
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y2M23D
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.16
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	27.12
CY2016	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	526015	shares
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-860000
CY2016	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2016	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016	dei	Document Period End Date DocumentPeriodEndDate	2016-12-31
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.35
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.174	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.004	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.020	pure
CY2016	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0237	pure
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	266863	shares
CY2016	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Significant estimates and assumptions by management affect the Company’s revenue recognition for multiple element arrangements, allowance for doubtful accounts, the net realizable value of inventory, estimated fair value of cost method investments, valuations and purchase price allocations related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, stock-based compensation, fair value estimates of contingent consideration, contingent liabilities, tax reserves and recoverability of the Company’s net deferred tax assets and related valuation allowance.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.</p> </div>
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001	pure
CY2016	dei	Entity Registrant Name EntityRegistrantName	REPLIGEN CORP
CY2016	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2016	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y11M19D
CY2016	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2021-12-31
CY2016	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	6000
CY2016	us-gaap	Gain Loss On Investments GainLossOnInvestments	0
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	6498000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4595000
CY2016	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	14135000
CY2016	us-gaap	Royalty Revenue RoyaltyRevenue	100000
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	15974000
CY2016	us-gaap	Net Income Loss NetIncomeLoss	11681000
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6163000
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3222000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	10.97
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	183619	shares
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y8M12D
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-8535000
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1713000
CY2016	us-gaap	Revenues Revenues	104541000
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4325000
CY2016	us-gaap	Investment Income Net InvestmentIncomeNet	346000
CY2016	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	236000
CY2016	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	15000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	18072000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	6514000
CY2016	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1841000
CY2016	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	104441000
CY2016	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	23700000
CY2016	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	798000
CY2016	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-5189000
CY2016	us-gaap	Income Taxes Paid IncomeTaxesPaid	3993000
CY2016	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	928000
CY2016	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-3242000
CY2016	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	2115000
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	118000
CY2016	us-gaap	Stock Issued1 StockIssued1	14135000
CY2016	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-5183000
CY2016	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	652000
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-612000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	16574000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-4882000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	11692000
CY2016	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-7000
CY2016	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	3242000
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4092000
CY2016	us-gaap	Depreciation Depreciation	3269000
CY2016	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-2299000
CY2016	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-3809000
CY2016	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	4027000
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11000
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1802000
CY2016	us-gaap	Interest Expense InterestExpense	3768000
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-49194000
CY2016	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	45000
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	4595000
CY2016	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	16000
CY2016	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2274000
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4077000
CY2016	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5334000
CY2016	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	3975000
CY2016	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	111070000
CY2016	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	30853000
CY2016	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-207000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	639000
CY2016	us-gaap	Costs And Expenses CostsAndExpenses	88567000
CY2016	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-4038000
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	112113000
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2664000
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7355000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5043000
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2052000
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	68141000
CY2016	us-gaap	Cost Of Goods Sold CostOfGoodsSold	47117000
CY2016	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	0
CY2016	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	4781000
CY2016	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2016	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-2031000
CY2016	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	43000
CY2016	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-326000
CY2016	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1981000
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1841000
CY2016	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	23400000
CY2016	rgen	Marketable Debt Securities Weighted Average Remaining Maturity Period MarketableDebtSecuritiesWeightedAverageRemainingMaturityPeriod	P3Y10M24D
CY2016	rgen	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Foreign Currency Translation Adjustments FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyTranslationAdjustments	-58000
CY2016	rgen	Lease Agreement Area LeaseAgreementArea	45000	sqft
CY2016	rgen	Nonrefundable Upfront Cash Payment Under Collaborations Agreement NonrefundableUpfrontCashPaymentUnderCollaborationsAgreement	2000000
CY2016	rgen	Lease Agreement Termination Description LeaseAgreementTerminationDescription	The Company terminated the lease on the 7,350 square feet of space in the first quarter of 2015.
CY2016	rgen	Amount To Be Received Upon Completion Of Transfer AmountToBeReceivedUponCompletionOfTransfer	125675
CY2016	rgen	Payment Of Contingent Consideration In Common Stock PaymentOfContingentConsiderationInCommonStock	875000
CY2016	rgen	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.048	pure
CY2016	rgen	Stock Issued During Period Value Contingent Considerations StockIssuedDuringPeriodValueContingentConsiderations	875000
CY2016	rgen	Number Of Buildings Leased NumberOfBuildingsLeased	4	Building
CY2016	rgen	Provision For Deferred Income Tax Expense Benefit ProvisionForDeferredIncomeTaxExpenseBenefit	-4066000
CY2016	rgen	Increase Decrease In Noncurrent Liabilities IncreaseDecreaseInNoncurrentLiabilities	-240000
CY2016	rgen	Long Term Marketable Securities Maturities Term Minimum LongTermMarketableSecuritiesMaturitiesTermMinimum	P1Y
CY2016	rgen	Income Tax Reconciliation Permanent Differences IncomeTaxReconciliationPermanentDifferences	567000
CY2014Q1	rgen	Non Contingent Consideration Being Recognized As Revenue Over Estimated Period Of Performance NonContingentConsiderationBeingRecognizedAsRevenueOverEstimatedPeriodOfPerformance	2000000
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
CY2015Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33451000	shares
CY2015Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32755000	shares
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.09
CY2015Q1	us-gaap	Revenues Revenues	20816000
CY2015Q1	us-gaap	Investment Income Net InvestmentIncomeNet	36000
CY2015Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	20816000
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	4039000
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	2929000
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	132000
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	4198000
CY2015Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1112000
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1269000
CY2015Q1	us-gaap	Interest Expense InterestExpense	9000
CY2015Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6024000
CY2015Q1	us-gaap	Costs And Expenses CostsAndExpenses	16777000
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1568000
CY2015Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	8073000
CY2015Q1	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	0
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.11
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33671000	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32870000	shares
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.11
CY2015Q2	us-gaap	Revenues Revenues	21457000
CY2015Q2	us-gaap	Investment Income Net InvestmentIncomeNet	19000
CY2015Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	21457000
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	4609000
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	3613000
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-269000
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	4351000
CY2015Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	768000
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	738000
CY2015Q2	us-gaap	Interest Expense InterestExpense	8000
CY2015Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6242000
CY2015Q2	us-gaap	Costs And Expenses CostsAndExpenses	16848000
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1252000
CY2015Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	8586000
CY2015Q2	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	0
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33494000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33025000	shares
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.05
CY2016Q1	us-gaap	Revenues Revenues	25094000
CY2016Q1	us-gaap	Investment Income Net InvestmentIncomeNet	61000
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	25094000
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	3463000
CY2016Q2	us-gaap	Costs And Expenses CostsAndExpenses	23311000
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1890000
CY2016Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	12644000
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33690000	shares
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32925000	shares
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.08
CY2015Q3	us-gaap	Revenues Revenues	19814000
CY2015Q3	us-gaap	Investment Income Net InvestmentIncomeNet	37000
CY2015Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	19814000
CY2016Q2	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	0
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.08
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	1625000
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-979000
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2540000
CY2016Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2005000
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	915000
CY2016Q1	us-gaap	Interest Expense InterestExpense	5000
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7018000
CY2016Q1	us-gaap	Costs And Expenses CostsAndExpenses	21631000
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1539000
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	11069000
CY2016Q1	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	0
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.11
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34175000	shares
CY2016Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33649000	shares
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.12
CY2016Q2	us-gaap	Revenues Revenues	29170000
CY2016Q2	us-gaap	Investment Income Net InvestmentIncomeNet	76000
CY2016Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	29170000
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	5859000
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	3872000
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	75000
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5372000
CY2016Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	637000
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1500000
CY2016Q2	us-gaap	Interest Expense InterestExpense	638000
CY2016Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8140000
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	3688000
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	2538000
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-38000
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3679000
CY2015Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	233000
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1141000
CY2015Q3	us-gaap	Interest Expense InterestExpense	8000
CY2015Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5959000
CY2015Q3	us-gaap	Costs And Expenses CostsAndExpenses	16126000
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1490000
CY2015Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	8444000
CY2015Q3	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	0
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34313000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33779000	shares
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2016Q3	us-gaap	Revenues Revenues	24677000
CY2016Q3	us-gaap	Investment Income Net InvestmentIncomeNet	97000
CY2016Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	24677000
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	3747000
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	1155000
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-75000
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2214000
CY2016Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	675000
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1059000
CY2016Q3	us-gaap	Interest Expense InterestExpense	1555000
CY2016Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7127000
CY2016Q3	us-gaap	Costs And Expenses CostsAndExpenses	20930000
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1886000
CY2016Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	11242000
CY2016Q3	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	0
CY2015Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2015Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33577000	shares
CY2015Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32946000	shares
CY2015Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2015Q4	us-gaap	Revenues Revenues	21449000
CY2015Q4	us-gaap	Investment Income Net InvestmentIncomeNet	44000
CY2015Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	21449000
CY2015Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	1428000
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	265000
CY2015Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-270000
CY2015Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1194000
CY2015Q4	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1969000
CY2015Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	929000
CY2015Q4	us-gaap	Interest Expense InterestExpense	8000
CY2015Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6473000
CY2015Q4	us-gaap	Costs And Expenses CostsAndExpenses	20021000
CY2015Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1431000
CY2015Q4	us-gaap	Cost Of Goods Sold CostOfGoodsSold	10148000
CY2015Q4	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	0
CY2016Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.15
CY2016Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34369000	shares
CY2016Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33833000	shares
CY2016Q4	us-gaap	Revenues Revenues	25600000
CY2016Q4	us-gaap	Investment Income Net InvestmentIncomeNet	112000
CY2016Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.15
CY2016Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	25500000
CY2016Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	2905000
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	5029000
CY2016Q4	us-gaap	Royalty Revenue RoyaltyRevenue	100000
CY2016Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	119000
CY2016Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1566000
CY2016Q4	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-75000
CY2016Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3463000
CY2016Q4	us-gaap	Interest Expense InterestExpense	1570000
CY2016Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8568000
CY2016Q4	us-gaap	Costs And Expenses CostsAndExpenses	22695000
CY2016Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2040000
CY2016Q4	us-gaap	Cost Of Goods Sold CostOfGoodsSold	12162000
CY2016Q4	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	0

Files In Submission

Name	View Source	Status
0001193125-17-054220-index-headers.html	Edgar Link	pending
0001193125-17-054220-index.html	Edgar Link	pending
0001193125-17-054220.txt	Edgar Link	pending
0001193125-17-054220-xbrl.zip	Edgar Link	pending
d319578d10k.htm	Edgar Link	pending
d319578dex211.htm	Edgar Link	pending
d319578dex231.htm	Edgar Link	pending
d319578dex311.htm	Edgar Link	pending
d319578dex312.htm	Edgar Link	pending
d319578dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g319578g53v25.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rgen-20161231.xml	Edgar Link	completed
rgen-20161231.xsd	Edgar Link	pending
rgen-20161231_cal.xml	Edgar Link	unprocessable
rgen-20161231_def.xml	Edgar Link	unprocessable
rgen-20161231_lab.xml	Edgar Link	unprocessable
rgen-20161231_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGEN
REPLIGEN CORP Stock $rgen

2015 Q4 Form 10-K Financial Statement

#000119312517054220 Filed on February 23, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGEN REPLIGEN CORP Stock $rgen

2015 Q4 Form 10-K Financial Statement

#000119312517054220 Filed on February 23, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGEN
REPLIGEN CORP Stock $rgen